{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:29:14Z","timestamp":1793946554571,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.eclinm.2026.104064","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:38:12Z","timestamp":1783629492000},"page":"104064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Temporal variability in outcomes of identical regimens across newly diagnosed myeloma trials: a systematic review"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9657-9130","authenticated-orcid":false,"given":"Hector A.","family":"Vaquera-Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Godara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mainou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas Ditzian","family":"Kugler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-5477","authenticated-orcid":false,"given":"Tomer","family":"Meirson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10068","key":"10.1016\/j.eclinm.2026.104064_bib1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.eclinm.2026.104064_bib2","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104064_bib3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104064_bib4","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104064_bib5","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.eclinm.2026.104064_bib6","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, Bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104064_bib7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejca.2022.05.041","article-title":"Survival in smouldering myeloma and symptomatic myeloma: is there an emerging will Rogers phenomenon?","volume":"172","author":"Chakraborty","year":"2022","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104064_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group","volume":"7","author":"Hillengass","year":"2017","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104064_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.87","article-title":"Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy","volume":"5","author":"Siontis","year":"2015","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104064_bib10","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104064_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1200\/JCO-25-00924","article-title":"Venetoclax-dexamethasone versus pomalidomide-dexamethasone in t(11;14)-Positive relapsed\/refractory multiple myeloma: primary results of the randomized, phase III CANOVA study","volume":"44","author":"Popat","year":"2026","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104064_bib12","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41571-023-00801-x","article-title":"A critical appraisal of the ATLAS trial of maintenance therapy for multiple myeloma: end points, censoring and equipoise","volume":"20","author":"Mohyuddin","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104064_bib13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.04.044","article-title":"Informative censoring of surrogate end-point data in phase 3 oncology trials","volume":"153","author":"Gilboa","year":"2021","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104064_bib14","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/jnci\/djae028","article-title":"Association of differential censoring with survival and suboptimal control arms among oncology clinical trials","volume":"116","author":"Hsu","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104064_bib15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/jamaoncol.2021.8206","article-title":"Biased evaluation in cancer drug trials-how use of progression-free survival as the primary end point can mislead","volume":"8","author":"Tannock","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2026.104064_bib16","series-title":"Guidance for sponsors, clinical investigators, and IRBs data retention when subjects withdraw from FDA-regulated clinical trials","year":"2008"},{"key":"10.1016\/j.eclinm.2026.104064_bib17","series-title":"Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man","year":"2012"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104064_bib18","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S1470-2045(24)00451-0","article-title":"Common sense oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials","volume":"26","author":"Gyawali","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.104064_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104529","article-title":"Outcomes in randomized controlled trials of therapeutic interventions for multiple myeloma: a systematic review","volume":"204","author":"Mainou","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104064_bib20","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104064_bib21","doi-asserted-by":"crossref","first-page":"e621","DOI":"10.1016\/S2352-3026(25)00162-0","article-title":"Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial","volume":"12","author":"Bringhen","year":"2025","journal-title":"Lancet Haematol"},{"issue":"26","key":"10.1016\/j.eclinm.2026.104064_bib22","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","article-title":"Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)","volume":"116","author":"Zonder","year":"2010","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2026.104064_bib23","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V130.Suppl_1.906.906","article-title":"Bortezomib, lenalidomide and low-dose dexamethasone (VRD) versus lenalidomide and low-dose dexamethasone (Ld) for newly-diagnosed multiple Myeloma- a randomized phase III study","volume":"130","author":"Mookerjee","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104064_bib24","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S1470-2045(25)00280-3","article-title":"Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial","volume":"26","author":"Manier","year":"2025","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104064_bib25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.eclinm.2026.104064_bib26","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104064_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.55630","article-title":"Reanalysis of urothelial cancer chemoimmunotherapy trials with differential censoring","volume":"8","author":"Meirson","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eclinm.2026.104064_bib28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104064_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12874-017-0436-z","article-title":"New methods for estimating follow-up rates in cohort studies","volume":"17","author":"Xue","year":"2017","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104064_bib30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000529824","article-title":"Survival trends in sorafenib for advanced hepatocellular carcinoma: a reconstructed individual patient data meta-analysis of randomized trials","volume":"12","author":"Tan","year":"2023","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104064_bib31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s43441-020-00194-4","article-title":"Disagreements between FDA and its oncologic Drugs Advisory Committee (ODAC)","volume":"55","author":"Ayon Verduzco","year":"2021","journal-title":"Ther Innov Regul Sci"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:49:20Z","timestamp":1793944160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026003172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"alternative-id":["S2589537026003172"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104064","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporal variability in outcomes of identical regimens across newly diagnosed myeloma trials: a systematic review","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104064"}}